| Trial ID: | L3924 |
| Source ID: | NCT03560323
|
| Associated Drug: |
Beta-Hydroxy-Butyrate
|
| Title: |
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
|
| Acronym: |
Protocol1
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Heart Failure|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Beta-hydroxy-butyrate
|
| Outcome Measures: |
Primary: Cardiac Function, Parameters of left ventricular (LV ) diastolic and systolic function, 300-360 minutes after the start of infusion | Secondary: Myocardial energetics, Myocardial glucose uptake, 300-360 minutes after the start of infusion
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
78
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2019-01-07
|
| Completion Date: |
2027-02
|
| Results First Posted: |
|
| Last Update Posted: |
2025-01-31
|
| Locations: |
Texas Diabetes Institute - University Health System, San Antonio, Texas, 78207, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03560323
|
